
Clinical Grand Rounds:

Herpes:

"Everything you wanted to know, but were afraid to ask"

Anthony J. Verachtert, O.D. Moyes Eye Center





What is a virus?

- * Small infectious (100 times smaller than bacteria) agent that can only replicate inside the living cells of organisms
- * Latin = "to poison"
- * "obligate intracellular parasites"

Herpes Virus Family

- * HSV 1 Cold sores and ophthalmic infections
- * HSV 2 Genital
- * HSV 3 Varicella-Zoster (chicken pox and shingles)
- * HSV 4 Epstein-Barr (mononucleosis)
- * HSV 5 Cytomegalovirus
- * HSV 6/7 exanthum subitum / roseola infantum
- * HSV 8 Kaposi's Sarcoma


Herpes Virus 1

- * "ubiquitous human pathogen"
- * causes both asymptomatic and symptomatic infection
- * both **HSV 1 & 2** can infect the eye, although typically HSV 1 is much more common
 - * exception: in neonates, 75% HSV 2
- * different viral strains may produce different patterns of ocular disease

HSV Epidemiology

- * Patients ask: How did I get it?
 - * Humans are the only natural reservoir of HSV
 - * close personal contact (mucous membranes and external skin)
 - * primary infection usually asymptomatic and is followed by latency in sensory ganglia (trigeminal ganglia)
 - * primary infection manifests only 1-6% of the time
 - * clinical appearance of an infection may represent reactivation of an earlier primary infection at a different end organ





Clinical Manifestations

- * Congenital -rare
- * Neonatal:
 - * usually HSV 2 passed on from mother
 - * 1500-2000 cases per year
- * Historically by the age of 5, 60% of the population has been infected with HSV although this is trending down due to pediatric vaccination

Herpetic Blepharitis

- * **focal vesicular lesions** on the eyelid with surrounding erythema (similar to that of a cold sore around the mouth)
- * will progress to ulceration and crusting
- * frequently seen along with conjunctivitis



Herpetic Blepharitis


- * Treatment:
 - * Oral antivirals x 7-10 days
 - * Topical antivirals? no data to support
 - * If misdiagnosed as normal blepharitis, antibiotic/ steroid combination will make HSV blepharitis worse
 - * Take home = if you see ulcerative blepharitis, think HSV

Herpetic Conjunctivitis

- * primary HSV can present as follicular conjunctivitis
 - * may be responsible for up to 23% of all cases
- * often self limiting, BUT can go on to subsequent keratitis
- * can see conjunctival dendritic ulcers with stain



* Geographic conjunctival dendrite



HSV Conjunctivitis

- * Treatment:
 - * Oral antivirals 7-10 days
 - * Topical antivirals? with consideration of expense, may be more than you need
 - * If treated with the Gold Standard for all conjunctivitis i.e. Tobradex, you will see worsening
 - * Take home =
 - * 1. Conjunctivitis can be from HSV
 - * 2. Stain all conjunctivitis to look for dendrites on conj or cornea
 - * 3. Followup conjunctivitis pts and warn if they worsen to RTC

HSV Keratitis


- * World Health Organization (WHO)
 - * Corneal Scarring/Blindness is 4th most common reason for visual loss on the planet
- * "one of the most challenging entities confronting the clinician"

Classification of HSV Keratitis

- 1. Infectious Epithelial Keratitis
- 2. Stromal Keratitis
- 3. Endothelialiitis
- 4. Neurotrophic Keratopathy

1. Corneal Vesicles

- * earliest epithelial lesion
- * minute, raised, clear vesicles
- * with time coalesce to form a raised, dendritic lesion
- * eventually becomes dendritic ulcer



- * HSV Dendrite
- terminal bulbs
- swollen epithelium at end bulbs
- ulcerated lesion


2. Dendritic ulcer:

- * most common presentation
- * "dendron" = tree
- * branching, linear lesion with <u>terminal bulbs and swollen epithelial borders</u> that contain live virus
- * true "ulcer" = loss of tissue extending through the basement membrane
- * differentiate between:
 - * healing epithelium / recurrent corneal erosion
 - * herpes zoster pseudodendrites

Dendritic ulcer:


- * staining patterns:
 - * NaFl will stain ulcerated base, but not terminal bulbs
 - * Rose bengal will stain swollen epithelial cells at the borders
 - * rose bengal is toxic to HSV, therefore do not use Rose bengal until after culturing

- * Dendritic ulcer:
 - * following resolution of the dendritic ulcer, epithelium will be abnormal for several weeks
 - * dendritic epitheliopathy, HSV footprinting



3. Geographic ulcer:

- * enlarged dendritic ulcer that is no longer linear
- * scalloped edges with swollen epithelial borders
- * differentiate between:
 - * epithelial defect
 - * neurotrophic ulcer
- * can be the result of steroid use on a dendritic ulcer



4. Marginal ulcer:

- * dendritic ulcers found near the peripheral cornea
- * tend to be more painful and symptomatic
- * more inflammation due to proximity of <u>limbal vessels</u>
- * can be harder to treat due to excessive inflammation
- * differentiate between:
 - * staph marginal ulcer

Marginal HSV

- * <u>infectious</u>, with secondary immune reaction
- * epithelial defect
- * vascularization
- * progresses centrally

VS.

Staph Marginal Infiltrate

- * immune response to staphylococcal antigen
- * does not start with epithelial defect
- * no vascularization
- * progresses circumferentially

Staph Marginal Infiltrate

no vasculariztion

no epithelial defect

spreads along limbus

- * Treatment options:
 - * 1. Debridement:
 - * will resolve in 2-3 days
 - * 2. Topical antivirals:
 - * will resolve in 7-10 days
 - * 3. Oral antivirals:
 - * will resolve in 7-10 days

Management: Topical Antivirals

Drug	Dosing	Cost per day
Trifluridine (Viroptic)	q2hr then qid	\$10
Ganciclovir (Zirgan)	5x/day then 3x	\$16

Management: Oral Antivirals

Drug	Dosing	Cost per day
Acyclovir	400mg 5 times per day	\$2
Valacylovir	500 mg 3 times per day	\$7
Famciclovir	500mg 3 times per day	\$7

Treatment for Infectious Epithelial Disease?

Debridement


- effective
- cheap
- no toxicity

Topical Antivirals

- effective
- expensive
- toxicity

Oral Antivirals

- effective
- cheap
- safe



Oral Antiviral Prophylaxis

- * Discuss option of prophylaxis with every patient
- * Shown to reduce recurrence by at least 50% and more current studies have indicated maybe 75%
- * Acyclovir 400mg BID po or Valtrex 500mg QD po
- * Who needs this?
 - * atopic patients?
 - * immunosuppressed patients?

- * Accounts for only 2% of initial episodes, BUT 20-48% of recurrent HSV disease
- * commonly confused and poorly categorized
- * goal in treatment is to limit stromal scarring

- * chronic, recurrent inflammation due to retained viral antigen within the stroma
- * stromal inflammation with (almost always) intact epithelium
- * may be focal, multifocal or diffuse in pattern
- * depending on the strain of virus, can lead to permanent stromal scarring
 - * leads to need for penetrating keratoplasty

- * Neovascularization
 - * can occur at any level of the stroma with varying degrees of inflammation
 - * lipid deposition can follow with subsequent scarring and loss of vision

- * can present days to years after initial infectious episode
- * clinical course is chronic, recurrent inflammation that can persist for years
- * long term topical steroids may be required to suppress inflammatory reaction and prevent significant vision loss




Treatment for HSV Stromal Keratitis?

- * Topical steroids
 - * How often? depends of severity of stromal inflammation
 - * Taper? Critical to taper slowly, and some patients may require permanent topical steroids to control inflammation
 - * Permanent steroids = must monitor IOP and cataract formation
- * Antivirals?
 - * topical vs. oral
 - * topical for up to 2 weeks
 - * oral for prolonged or prophylactic treatment

Endotheliitis

- * inflammatory reaction at the level of the endothelium
- * epithelial edema, stromal edema, underlying keratic precipitates and iritis
- * absence of stromal infiltrate or neovascularization
- * can have endothelial cell loss with resulting corneal edema
- * thought to be immunologic reaction and responds with topical steroids



Treatment HSV endotheliitis?

- * Topical steroids
 - * How often? depends of severity of stromal inflammation
 - * Taper? Critical to taper slowly, and some patients may require permanent topical steroids to control inflammation
 - * Permanent steroids = must monitor IOP and cataract formation
- * Antivirals?
 - * topical vs. oral
 - * topical for up to 2 weeks
 - * oral for prolonged or prophylactic treatment

Neurotrophic keratopathy

- * patients who have had herpes keratitis are at risk to develop neurotrophic keratopathy
- * neither immune nor infectious
- * impaired corneal innervation in combination with decreased tear secretion

How to check corneal sensation?



Neurotrophic keratopathy

- * irregularity of the corneal surface
- * loss of corneal epithelial clarity
- * punctate erosions that develop into persistent epithelial defects
 - * oval epithelial defect with smooth borders
 - * epithelium at edge of defect will become **gray-white** with rolled/thickened edges
- * continuation of the epithelial defect will lead to stromal ulceration
 - = loss of tissue

epithelial breakdown and defect

/ White epithelium

Loss of epithelial clarity

Neurotrophic Keratopathy

- * Treatment Options:
 - * Lubrication
 - * Punctal plug
 - * Debridement and bandage contact lens
 - * Amniotic membrane
 - * Serum tears




Iridocyclitis

- * patients with HSV keratitis may develop a concomitant or subsequent iridocyclitis
- * can be the primary episode (no history of keratitis)
- * in addition to typical AC reaction and endothelial KP, often find segmental iris atrophy
- * HSV has been loosely linked as a possible cause of:
 - * Iridocorneal endothelial syndrome ICE
 - * Fuch's heterochromic iridocyclitis
 - * Posner-Schlossman syndrome

Iridocyclitis

- * frequently see IOP spike due to trabeculitis that responds well to topical steroids
- * chronic inflammation often leads to secondary glaucoma
- * these patients may respond well to oral antivirals



Treatment of HSV Iridiocyclitis

- * For most:
 - * Topical steroids
- * Some will ALSO need:
 - * Oral antivirals
- * Trabeculitis leads to IOP spikes
 - * may need glaucoma medications, BUT it is the steroid that will decrease trabeculitis and improve IOP

Diagnosis

- * relies heavily on ophthalmic examination
- * viral cell culture:
 - * early culturing
 - * may take a week to grow
 - * yield will be reduced if previous antiviral therapy has been used
 - * high false negatives

Diagnosis

- * Immunologic tests:
 - * Herpcheck
 - * Virogenlatex agglutination
 - * enzyme immunofiltration
 - * 1-hour enzyme linked immunoassay
- * studies haven't found any increase in sensitivity with addition of the above tests in addition to clinical examination

Diagnosis

- * Polymerase Chain Reaction PCR:
 - * equally sensitive and maybe more sensitive than cell culture
 - * 24-48hr results
- * Serum antibody titers:
 - * can be used to differentiate primary infection from recurrent disease

Management

- * Herpectic Eye Disease Study HEDS:
 - * multi-center, randomized, placebo-controlled study
- * Address following questions:
 - 1. Topical corticosteroids in treating stromal keratitis already on topical antivirals
 - 2. Oral acyclovir in treating stromal keratitis already on a topical steroid and antiviral
 - 3. Oral acyclovir in treating iridocyclitis already on topical steroid
 - 4. Oral acyclovir in preventing recurrence of epithelial and stromal keratitis
 - 5. Demographic and disease-specific predictors of recurrent HSV keratitis
 - 6. Risk factors for recurrence of ocular HSV

Topical corticosteroids in treating stromal keratitis already on a topical antiviral

- * topical corticosteroids helped in the treatment of stromal keratitis
- * failures related to tapering schedule of topical steroids
 - * need to slowly taper on a gradual, individualized basis

Oral acyclovir in treating stromal keratitis already on a topical steroid and antiviral

* no benefit to adding oral antiviral when already on topical steroid and antiviral for treatment of stromal keratitis

Oral acyclovir in treating iridocyclitis already on topical steroid

- * hard time recruiting these patients and this arm was discontinued with incomplete participation
- * difficult to notice benefit because patients with stromal keratitis and iridocyclitis were both in the is group
 - * stromal keratitis is thought to be immunologic and wouldn't be expected to benefit from oral antivirals
 - * iridocyclitis is thought to be infectious and would expect to benefit from oral antivirals

Oral acyclovir in preventing recurrence of epithelial and stromal keratitis

- * 400mg BID po acyclovir for 1 year
- * decreased recurrence of ocular HSV by 50%
- * applied to both epithelial and stromal keratitis
 - * greater effect with stromal keratitis with history of a prior episode
- * stromal keratitis more likely to recur compared to epithelial keratitis

Demographic and risk factors for recurrence

* Stress, systemic infection, sunlight exposure, menstruation, contact lens wear and eye injury WERE NOT deemed significant

So what DID HEDS tell us?

- * Oral antivirals reduces recurrences of epithelial and stromal keratitis
- * Topical steroids benefit stromal keratitis
- * Oral antivirals may help iridocyclitis
- * Prophylactic oral antivirals help prevent recurrences of herpectic keratitis, particularly in those with repeated stromal keratitis

Incidence, recurrence and outcomes of herpes simplex virus eye disease in Olmsted county, Minnesota 1976-2007

- * Leading infectious cause of corneal blindness
- * 394 cases initial presentation:
 - * Dendritic epithelial keratitis (59%)
 - * Other keratitis (16%)
 - * Blepharoconjunctivitis (20%)
 - * Conjunctivitis (4%)
 - * Uveitis (0.5%)

* Bilateral involvement (4%)

40.5%

Incidence, recurrence and outcomes of herpes simplex virus eye disease in Olmsted county, Minnesota 1976-2007

- * Likelihood of recurrence after initial episode:
 - * 27% at 1 year
 - * 50% at 5 years
 - * 63% at 20 years
- * Of those that had a first occurrence (169), (108) had second:
 - * 38% at 1 year
 - * 67% at 5 years
 - * 83% at 20 years

Incidence, recurrence and outcomes of herpes simplex virus eye disease in Olmsted county, Minnesota 1976-2007

- * 44% treated with prophylactic (400mg acyclovir bid po):
 - * Decreased risk of first reoccurrence by 2.9
- * If not treated prophylactically:
 - * 9.4x more likely to have epithelial keratitis
 - * 8.4x more likely to have stromal keratitis
 - * 34.5x more likely to have blepharitis/conjunctivitis

Herpes Zoster

- * varicella-zoster virus = Herpes Virus 3
- * Causes two distinct conditions:
 - * Varicella (Chickenpox) primary infection
 - * Herpes Zoster (Shingles) reactivation of latent virus

Varicella: Epidemiology

- * serological evidence of prior VZV infection is present in 95% of US
- * 4 million cases per year before vaccinations beginning in 1995
- * Since vaccine, 57-90% decrease in varicella

Zoster: Epidemiology

- * life time risk 10-30%
- * 500,000 cases annually
- * Effect of the zoster vaccine yet to be determined
- * Increasing age and altered immunity a significant risk factor

Varicella-Zoster Virus

- * Humans the only known natural reservoir
- * VZV is among the smallest within the herpes virus family
- * Remains latent within ganglion cells and neurons
- * With reactivation, virus spreads to the skin and mucous membranes
- * Abnormal skin sensations, pain and tenderness followed by the characteristic unilateral dermatomal eruption

Varicella-Zoster Virus

- * Involves the lower thoracic and upper lumbar dermatomes in 50%
- * 13-20% cases involve cranial nerves
 - * trigeminal nerve most frequently

Clinical Findings: Varicella

- * characteristic rash
 - * small red papules progressing to vesicular lesions
 - * usually more numerous on face and trunk
 - * rarely, found on mucosal surfaces

Ophthalmic Findings: Varicella


- * vesicular eruption on periocular skin and eyelids is common
- * can also involve conjunctiva and cornea
 - * papillary conjunctivitis
 - * punctate or dendritic keratitis
 - * disciform keratitis

Clinical Findings: Herpes Zoster

- * 1-4 days of prodromal symptoms:
 - * fever, malaise, headache, pain, itching, burning, erythema in affected dermatome
- * Macular rash which becomes papular and then vesicular within 24 hours
- * Usually involve one dermatome, but can include up to 3 adjacent
- * Vesicles may continue to develop over 4 days and longer in immunocompromised patients
- * after 2-3 weeks the acute phase subsides and the rash will crust over with the chance of persistent pain known as post-herpectic neuralgia

Clinical Findings: Herpes Zoster Ophthalmicus

- * Reactivation from the trigeminal ganglia with ocular involvement
- * 3 division of the trigeminal nerve (ophthalmic, maxillary and mandibular)
 - * ophthalmic most commonly affected (8-56%)
- * Opthalmic divides into
 - * nasociliary
 - * frontal (most commonly affected)
 - * lacrimal



Clinical Findings: Herpes Zoster Ophthalmicus

- * Nasociliary nerve:
 - * innnervates: anterior and posterior ethmoidal sinuses, the skin of the eyelids, the tip of the nose, conjunctiva, sclera, cornea, iris and choroid
 - * if nasociliary is involved = 50-75% chance of ocular complications
 - * Hutchinson's sign

Ophthalmic Manifestations: Periocular skin and eyelids



Maculopapular rash

Lid edema 4

Ophthalmic Manifestations: Periocular skin and eyelids

Vesicular rash

- vesicles can be cultured
- can lead to significant scarring



Maculopapular rash


Lid edema

can be confused with presental cellulitis

Ophthalmic Manifestations: Periocular skin and eyelids

Vesicular rash

- vesicles can be cultured
- can lead to significant scarring



Maculopapular rash

Lid edema

• can be confused with preseptal cellulitis

Opthalmic Manifestations: Conjunctiva and Sclera



conjunctivitis



episcleritis



scleritis


Clinical Manifestations: Cornea


Corneal Change	Frequency	Onset
punctate keratitis	50%	2 days
pseudodendrites	50%	4-6 days
anterior stromal keratitis	40%	10 days
endotheliitis	34%	7 days
Serpiginous ulcer	7%	1 month
Sclerokeratitis	1%	1 month
Corneal mucous plaques	13%	2-3 months
Disciform keratitis	10%	3-4 months
Neurotrophic keratitis	25%	2 months
Exposure keratopathy	11%	2-3 months
Interstitial Keratitis/ Lipid	15%	1-2 years
Permanent Corneal Edema	5%	1-2 years


Clinical Manifestations: Cornea

pseudodendrites

punctate epithelial keratitis








Early Corneal Findings

- * Punctate epithelial keratitis:
 - * blotchy, swollen epithelial cells
- * Pseudodendrites:
 - * "dendritic" shaped lesions of raised epithelial cells
 - * superficial, with ill defined endings
 - * lack well defined terminal bulbs
 - * no central ulceration



Late Corneal Findings

- * Neurotrophic Keratitis:
 - * loss of corneal sensation leads to loss of epithelial integrity with subsequent epithelial breakdown
 - * some people regain normal sensation, some never regain total sensation and others continue to worsen
 - * 20% will have some loss of corneal sensation

Late Corneal Findings

Lipid -Keratopathy

Interstitial Keratitis

After weeks of topical steroids

Ghost vessels

Interstitial Keratitis and Lipid Keratopathy

- * extensive corneal inflammation
- * new blood vessels grow within corneal stroma
- * vessels leak inflammatory cells and eventual lipid
- * can progress to cause permanent corneal opacification

Keratouveitis

- * seen in up to 40% of HZO patients
- * extensive keratic precipitates, corneal edema and posterior synechiae
- * 56% will have secondary glaucoma

